Experienced in Olfactory Neuroblastoma

Koji Ushiro

Department Of Otolaryngology Head & Neck Surgery, 1-1 Mukaihata Cho, Fukakusa, 
Fushimi, JP 
Experienced in Olfactory Neuroblastoma
Department Of Otolaryngology Head & Neck Surgery, 1-1 Mukaihata Cho, Fukakusa, 
Fushimi, JP 
OverviewLocationsClinical Research

Overview

Koji Ushiro practices in Fushimi, Japan. Mr. Ushiro is rated as an Experienced expert by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Adenoid Cystic Carcinoma, Salivary Gland Tumors, Olfactory Neuroblastoma, and Endoscopy.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Olfactory Neuroblastoma.

Gender
Male

Locations

Department Of Otolaryngology Head & Neck Surgery, 1-1 Mukaihata Cho, Fukakusa, Fushimi, 6128555, Japan
Other Locations
Department Of Otolaryngology Head & Neck Surgery, Kyoto, Japan
Department Of Otorhinolaryngology Head & Neck Surgery, Japan
Department Of Otorhinolaryngology Head & Neck Surgery, Moriyama, 5248524, Japan
Otsu, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3

18 Total Publications

Prediction model of ipsilateral level II lymph node metastasis in papillary thyroid carcinoma.
Prediction model of ipsilateral level II lymph node metastasis in papillary thyroid carcinoma.
Journal: Auris, nasus, larynx
Published: March 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ushiro's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile